Global MET Inhibitors for Lung Cancer Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2030

Table of Contents

1 Market Overview
    1.1 MET Inhibitors for Lung Cancer Introduction
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global MET Inhibitors for Lung Cancer Consumption Value by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Savolitinib
        1.3.3 Tepotinib
        1.3.4 Other
    1.4 Market Analysis by Application
        1.4.1 Overview: Global MET Inhibitors for Lung Cancer Consumption Value by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Hospital
        1.4.3 Drug Center
        1.4.4 Others
    1.5 Global MET Inhibitors for Lung Cancer Market Size & Forecast
        1.5.1 Global MET Inhibitors for Lung Cancer Consumption Value (2019 & 2022 & 2030)
        1.5.2 Global MET Inhibitors for Lung Cancer Sales Quantity (2019-2030)
        1.5.3 Global MET Inhibitors for Lung Cancer Average Price (2019-2030) 
2 Manufacturers Profiles
    2.1 Pfizer
        2.1.1 Pfizer Details
        2.1.2 Pfizer Major Business
        2.1.3 Pfizer MET Inhibitors for Lung Cancer Product and Services
        2.1.4 Pfizer MET Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.1.5 Pfizer Recent Developments/Updates
    2.2 Novartis
        2.2.1 Novartis Details
        2.2.2 Novartis Major Business
        2.2.3 Novartis MET Inhibitors for Lung Cancer Product and Services
        2.2.4 Novartis MET Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.2.5 Novartis Recent Developments/Updates
    2.3 Eli Lilly and Company
        2.3.1 Eli Lilly and Company Details
        2.3.2 Eli Lilly and Company Major Business
        2.3.3 Eli Lilly and Company MET Inhibitors for Lung Cancer Product and Services
        2.3.4 Eli Lilly and Company MET Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.3.5 Eli Lilly and Company Recent Developments/Updates
    2.4 Merck KGaA
        2.4.1 Merck KGaA Details
        2.4.2 Merck KGaA Major Business
        2.4.3 Merck KGaA MET Inhibitors for Lung Cancer Product and Services
        2.4.4 Merck KGaA MET Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.4.5 Merck KGaA Recent Developments/Updates
    2.5 AstraZeneca
        2.5.1 AstraZeneca Details
        2.5.2 AstraZeneca Major Business
        2.5.3 AstraZeneca MET Inhibitors for Lung Cancer Product and Services
        2.5.4 AstraZeneca MET Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.5.5 AstraZeneca Recent Developments/Updates
    2.6 Takeda Pharmaceutical
        2.6.1 Takeda Pharmaceutical Details
        2.6.2 Takeda Pharmaceutical Major Business
        2.6.3 Takeda Pharmaceutical MET Inhibitors for Lung Cancer Product and Services
        2.6.4 Takeda Pharmaceutical MET Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.6.5 Takeda Pharmaceutical Recent Developments/Updates
    2.7 Daiichi Sankyo
        2.7.1 Daiichi Sankyo Details
        2.7.2 Daiichi Sankyo Major Business
        2.7.3 Daiichi Sankyo MET Inhibitors for Lung Cancer Product and Services
        2.7.4 Daiichi Sankyo MET Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.7.5 Daiichi Sankyo Recent Developments/Updates
    2.8 Kyowa Kirin
        2.8.1 Kyowa Kirin Details
        2.8.2 Kyowa Kirin Major Business
        2.8.3 Kyowa Kirin MET Inhibitors for Lung Cancer Product and Services
        2.8.4 Kyowa Kirin MET Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.8.5 Kyowa Kirin Recent Developments/Updates
    2.9 HUTCHMED
        2.9.1 HUTCHMED Details
        2.9.2 HUTCHMED Major Business
        2.9.3 HUTCHMED MET Inhibitors for Lung Cancer Product and Services
        2.9.4 HUTCHMED MET Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.9.5 HUTCHMED Recent Developments/Updates
    2.10 Beyotime Biotechnology
        2.10.1 Beyotime Biotechnology Details
        2.10.2 Beyotime Biotechnology Major Business
        2.10.3 Beyotime Biotechnology MET Inhibitors for Lung Cancer Product and Services
        2.10.4 Beyotime Biotechnology MET Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.10.5 Beyotime Biotechnology Recent Developments/Updates
    2.11 Haihe Biopharma
        2.11.1 Haihe Biopharma Details
        2.11.2 Haihe Biopharma Major Business
        2.11.3 Haihe Biopharma MET Inhibitors for Lung Cancer Product and Services
        2.11.4 Haihe Biopharma MET Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.11.5 Haihe Biopharma Recent Developments/Updates
3 Competitive Environment: MET Inhibitors for Lung Cancer by Manufacturer
    3.1 Global MET Inhibitors for Lung Cancer Sales Quantity by Manufacturer (2019-2022)
    3.2 Global MET Inhibitors for Lung Cancer Revenue by Manufacturer (2019-2022)
    3.3 Global MET Inhibitors for Lung Cancer Average Price by Manufacturer (2019-2022)
    3.4 Market Share Analysis (2021)
        3.4.1 Producer Shipments of MET Inhibitors for Lung Cancer by Manufacturer Revenue ($MM) and Market Share (%): 2021
        3.4.2 Top 3 MET Inhibitors for Lung Cancer Manufacturer Market Share in 2021
        3.4.2 Top 6 MET Inhibitors for Lung Cancer Manufacturer Market Share in 2021
    3.5 MET Inhibitors for Lung Cancer Market: Overall Company Footprint Analysis
        3.5.1 MET Inhibitors for Lung Cancer Market: Region Footprint
        3.5.2 MET Inhibitors for Lung Cancer Market: Company Product Type Footprint
        3.5.3 MET Inhibitors for Lung Cancer Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
    4.1 Global MET Inhibitors for Lung Cancer Market Size by Region
        4.1.1 Global MET Inhibitors for Lung Cancer Sales Quantity by Region (2019-2030)
        4.1.2 Global MET Inhibitors for Lung Cancer Consumption Value by Region (2019-2030)
        4.1.3 Global MET Inhibitors for Lung Cancer Average Price by Region (2019-2030)
    4.2 North America MET Inhibitors for Lung Cancer Consumption Value (2019-2030)
    4.3 Europe MET Inhibitors for Lung Cancer Consumption Value (2019-2030)
    4.4 Asia-Pacific MET Inhibitors for Lung Cancer Consumption Value (2019-2030)
    4.5 South America MET Inhibitors for Lung Cancer Consumption Value (2019-2030)
    4.6 Middle East and Africa MET Inhibitors for Lung Cancer Consumption Value (2019-2030)
5 Market Segment by Type
    5.1 Global MET Inhibitors for Lung Cancer Sales Quantity by Type (2019-2030)
    5.2 Global MET Inhibitors for Lung Cancer Consumption Value by Type (2019-2030)
    5.3 Global MET Inhibitors for Lung Cancer Average Price by Type (2019-2030)
6 Market Segment by Application
    6.1 Global MET Inhibitors for Lung Cancer Sales Quantity by Application (2019-2030)
    6.2 Global MET Inhibitors for Lung Cancer Consumption Value by Application (2019-2030)
    6.3 Global MET Inhibitors for Lung Cancer Average Price by Application (2019-2030)
7 North America
    7.1 North America MET Inhibitors for Lung Cancer Sales Quantity by Type (2019-2030)
    7.2 North America MET Inhibitors for Lung Cancer Sales Quantity by Application (2019-2030)
    7.3 North America MET Inhibitors for Lung Cancer Market Size by Country
        7.3.1 North America MET Inhibitors for Lung Cancer Sales Quantity by Country (2019-2030)
        7.3.2 North America MET Inhibitors for Lung Cancer Consumption Value by Country (2019-2030)
        7.3.3 United States Market Size and Forecast (2019-2030)
        7.3.4 Canada Market Size and Forecast (2019-2030)
        7.3.5 Mexico Market Size and Forecast (2019-2030)
8 Europe
    8.1 Europe MET Inhibitors for Lung Cancer Sales Quantity by Type (2019-2030)
    8.2 Europe MET Inhibitors for Lung Cancer Sales Quantity by Application (2019-2030)
    8.3 Europe MET Inhibitors for Lung Cancer Market Size by Country
        8.3.1 Europe MET Inhibitors for Lung Cancer Sales Quantity by Country (2019-2030)
        8.3.2 Europe MET Inhibitors for Lung Cancer Consumption Value by Country (2019-2030)
        8.3.3 Germany Market Size and Forecast (2019-2030)
        8.3.4 France Market Size and Forecast (2019-2030)
        8.3.5 United Kingdom Market Size and Forecast (2019-2030)
        8.3.6 Russia Market Size and Forecast (2019-2030)
        8.3.7 Italy Market Size and Forecast (2019-2030)
9 Asia-Pacific
    9.1 Asia-Pacific MET Inhibitors for Lung Cancer Sales Quantity by Type (2019-2030)
    9.2 Asia-Pacific MET Inhibitors for Lung Cancer Sales Quantity by Application (2019-2030)
    9.3 Asia-Pacific MET Inhibitors for Lung Cancer Market Size by Region
        9.3.1 Asia-Pacific MET Inhibitors for Lung Cancer Sales Quantity by Region (2019-2030)
        9.3.2 Asia-Pacific MET Inhibitors for Lung Cancer Consumption Value by Region (2019-2030)
        9.3.3 China Market Size and Forecast (2019-2030)
        9.3.4 Japan Market Size and Forecast (2019-2030)
        9.3.5 Korea Market Size and Forecast (2019-2030)
        9.3.6 India Market Size and Forecast (2019-2030)
        9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
        9.3.8 Australia Market Size and Forecast (2019-2030)
10 South America
    10.1 South America MET Inhibitors for Lung Cancer Sales Quantity by Type (2019-2030)
    10.2 South America MET Inhibitors for Lung Cancer Sales Quantity by Application (2019-2030)
    10.3 South America MET Inhibitors for Lung Cancer Market Size by Country
        10.3.1 South America MET Inhibitors for Lung Cancer Sales Quantity by Country (2019-2030)
        10.3.2 South America MET Inhibitors for Lung Cancer Consumption Value by Country (2019-2030)
        10.3.3 Brazil Market Size and Forecast (2019-2030)
        10.3.4 Argentina Market Size and Forecast (2019-2030)
11 Middle East & Africa
    11.1 Middle East & Africa MET Inhibitors for Lung Cancer Sales Quantity by Type (2019-2030)
    11.2 Middle East & Africa MET Inhibitors for Lung Cancer Sales Quantity by Application (2019-2030)
    11.3 Middle East & Africa MET Inhibitors for Lung Cancer Market Size by Country
        11.3.1 Middle East & Africa MET Inhibitors for Lung Cancer Sales Quantity by Country (2019-2030)
        11.3.2 Middle East & Africa MET Inhibitors for Lung Cancer Consumption Value by Country (2019-2030)
        11.3.3 Turkey Market Size and Forecast (2019-2030)
        11.3.4 Egypt Market Size and Forecast (2019-2030)
        11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
        11.3.6 South Africa Market Size and Forecast (2019-2030)
12 Market Dynamics
    12.1 MET Inhibitors for Lung Cancer Market Drivers
    12.2 MET Inhibitors for Lung Cancer Market Restraints
    12.3 MET Inhibitors for Lung Cancer Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry
    12.5 Influence of COVID-19 and Russia-Ukraine War
        12.5.1 Influence of COVID-19
        12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
    13.1 Raw Material of MET Inhibitors for Lung Cancer and Key Manufacturers
    13.2 Manufacturing Costs Percentage of MET Inhibitors for Lung Cancer
    13.3 MET Inhibitors for Lung Cancer Production Process
    13.4 MET Inhibitors for Lung Cancer Industrial Chain
14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 MET Inhibitors for Lung Cancer Typical Distributors
    14.3 MET Inhibitors for Lung Cancer Typical Customers
15 Research Findings and Conclusion
16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer